TOKYO, Dec 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval for “URECE®” (brand name in China: “优乐思®”, generic name: dotinurad) from the National Medical ...
ABP-671 is a class 1 innovative chemotherapeutic drug for the treatment of gout and hyperuricemia, currently in Phase 2b/3 clinical trials for gout in China and overseas. The Product reduces renal ...